U.S. Markets closed

Bayer Aktiengesellschaft (BAYN.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
44.33-0.48 (-1.07%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close44.81
Bid44.35 x 28400
Ask44.36 x 2100
Day's Range44.15 - 45.17
52 Week Range43.18 - 78.34
Avg. Volume3,504,266
Market Cap43.551B
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-5.72
Earnings DateNov 03, 2020
Forward Dividend & Yield2.80 (6.25%)
Ex-Dividend DateApr 29, 2020
1y Target Est119.69
  • Reuters

    Bayer's Orbia plans Latam expansion after Bunge deal in Brazil

    Orbia, an online farm products trade platform majority owned by Germany's Bayer AG, is betting that a deal with U.S. grain merchant Bunge Ltd will pave the way for a planned international foray, Chief Executive Ivan Moreno said on Monday. Under the partnership with Bunge announced in September, Orbia's 170,000 registered farm users in Brazil can sell produce online to the U.S. firm, which secured exclusive origination rights to the platform. Moreno, a former Bayer executive, said in an interview the deal allows farmers to sell corn and soy on the futures or spot market in exchange for cash or credit to buy inputs on Orbia for use in future seasons, a transaction typically known as "barter."

  • Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study

    Bayer's Aliqopa Meets Primary Endpoint in Lymphoma Study

    Bayer's (BAYRY) Aliqopa combined with Rituxan met the primary endpoint of significantly prolonging PFS in a phase III study in patients with relapsed indolent non-Hodgkin's lymphoma.

  • Better Buy: Biogen vs. Bayer
    Motley Fool

    Better Buy: Biogen vs. Bayer

    Bayer Aktiengesellschaft (OTC: BAYRY) and Biogen (NASDAQ: BIIB) are both massive and multinational healthcare companies, but the case in favor of investing in each company is dramatically different. Whereas Biogen's stock requires a steady drumbeat of new drug approvals and rising revenues from drug sales, Bayer relies heavily on the power of its deeply entrenched healthcare brands and agrochemical business to expand sales in global markets.